1. Cyclofenil diphenol (F6060), a weak non-steroidal oestrogen, was shown previously to inhibit [35S]proteoglycan synthesis [Mason, Lineham, Phillipson & Black (1984) Biochem. J. 223,[401][402][403][404][405][406][407][408][409][410][411][412] inhibits polymerization ofchondroitin sulphate on top-nitrophenyl ,J-xyloside even when the chondrocytes are loaded with the initiator prior to treatment. 3. Cyclofenil diphenol interferes with the cellular uptake of amino acids via the system A carrier, as shown by inhibition of uptake of methylaminoisobutyric acid, a specific substrate for this system. The drug had no effect on the uptake of 2-deoxyglucose by the cells. 
INTRODUCTION
In previous studies we have found that cyclofenil diphenol, in the presence of concentrations of albumin just sufficient to keep it in solution (30 ,ug [1] . Ultrastructural investigations showed that when Swarm chondrosarcoma chondrocytes are exposed to cyclofenil diphenol under the latter conditions, their normally well-developed Golgi stacks fragment into smaller vesicles and disappear. At a later stage the rough endoplasmic reticulum in such cells dilates into large ribosome-studded vesicles which contain accumulations of electron-dense material, identified tentatively as newly synthesized protein [2] .
The present report shows that the inhibitory properties of cyclofenil diphenol on proteoglycan synthesis are shared by other synthetic oestrogen analogues, and indicates that this compound is an inhibitor of glycosaminoglycan chain polymerization. However, we also demonstrate that the drug has an inhibitory action on the system A transporter for amino acid uptake by the chondrocytes. Additionally, high concentrations of the drug bring about a decrease in the pool size of UDP-sugars required for proteoglycan, hyaluronate and glycoprotein synthesis.
MATERIALS AND METHODS

Preparation of primary chondrocyte cultures
Chondrocytes were isolated from the Swarm rat chondrosarcoma by the method of Kimura et al. [3] ; cells were plated at 4 x 106/35 mm2 Petri dish (day 0) in Dulbecco's modified Eagle's medium (DMEM) containing 15 % foetal calf serum, penicillin and streptomycin (100 units/ml) (Gibco Ltd.), Hepes (15 mM) , Tes (10 mM) and Bes (10 mM) (all from BDH Chemicals Ltd.). Chondrocyte cultures were used on either day 1 or day 2, the medium being changed to DMEM containing insulin (100 ng/ml) (Wellcome Foundation Ltd.) at least 1 h before the start of experiments.
Treatment of cultures with cyclofenil diphenol and labelling procedures
Cyclofenil diphenol (F6060) (Ferrosan AB, Malmo, Sweden) was dissolved in 1 M-NaOH and diluted immediately with DMEM containing 50 mg of BSA/ml (Sigma Chemical Co.; product no. A4503) to give a stock solution of concentrations 450 ,ug of drug and 20 mg of albumin/ml [1] . A fresh solution was made for each experiment.
Chondrocyte cultures were treated with various concentrations of cyclofenil diphenol (40-100 ,ug/ml) in DMEM containing the supplements listed above and a constant drug/albumin ratio. The treatment period was usually 3 h. During the last 1 [4] .
Radioiodination of albumin for uptake studies "251-labelled albumin was prepared using the lodoGen procedure [5] .
UDP-sugar analysis
The (10 mM) and heating at 100 'C for 10 min [6] . Concentrated lysis buffer was added to media to give the same final concentration as for the cell layer extract, and the media were treated in the same way. After cooling, iodoacetamide (20 mM) was added and the samples were incubated in the dark for 2 h.
Portions of the treated cell layer extracts and media were diluted with 20 vol. of dilution buffer containing Nonidet P-40 and sodium deoxycholate, together with protease inhibitors [6] . Undissolved [6] . At the end of the incubation, samples were centrifuged (1500 g, O min, 4 C), and washed four times in dilution buffer containing 0.1 % SDS at 4°C (10 min per wash). Control samples were precipitated with non-immunized rabbit serum by the same procedure.
Immunoprecipitates were treated with 0.5 M-NaOH for 20 min to release antigens and antibodies from S. aureus membranes.
The supernatant was neutralized (0.1 vol. of 5 M-acetic acid/I MTris/HCI, pH 7.4) and portions were counted for 3H radioactivity by liquid scintillation.
Samples were prepared for SDS/PAGE by resuspending the immunoprecipitate in 10 mM-Tris/HCI, pH 6.8. After centrifugation (1500 g, 4°C, O min) this was repeated twice more before lyophilizing the pellet and resuspending it in 2 % SDS/62.5 mM-Tris/HCI (pH 6.8)/10% glycine/dithiothreitol (20 mg/ml). After boiling for 5 min and centrifuging (1500 g, 10 min, room temperature), the supernatant was analysed by SDS/PAGE on 8 % slab gels. Bands were detected by fluorography and fluorograms were scanned with a laser scanner.
RESULTS
Under conditions of albumin excess, cyclofenil diphenol (F6060) inhibits proteoglycan synthesis in a dose-dependent manner, whereas protein synthesis is only partially inhibited [1] . To investigate the specificity of this effect, we compared the action of the closely related compounds bis-(p-hydroxyphenyl)-2-methylcyclohexylidenemethane (F6204) and bis-(phydroxyphenyl)cyclohexylmethane (F6091) on these pathways with that of cyclofenil (Fig. 1) To test whether the albumin used to solubilize the drugs was taken up by the chondrocytes, cultures were incubated at either 37°C or 0°C for 2 h in medium containing either 12511 albumin-cyclofenil complex or 251I-albumin alone. Then, after washing the cell layers rapidly three times with medium containing unlabelled albumin-drug complex or albumin alone, followed by extraction of the extracellular matrix with 4 Mguanidine hydrochloride, the residual cells were solubilized with 4 % CHAPS74 m-guanid-ine hydrochloride and radi'oactivity was measured. Of the total 251I-albumin radioactivity, 0.60-0.65 % was associated with the cell fraction under all conditions, suggesting that albumin is not actively internalized and that cyclofenil diphenol enters the cells in a free form.
Swarm chondrocytes synthesize a large chondroitin 4-sulphate proteoglycan (85-90 % of total) and a much smaller proteoglycan (10-15 %) of lower density which is enriched in chondroitin 6-sulphate [4, 7] . These are readily separated by chromatography on Sepharose CL 2B under dissociative conditions [1, 7] . Previous experiments with a minimum albumin/drug ratio (30: 1, w/w) suggested that synthesis of the chondroitin 6-sulphate proteoglycan was less susceptible to inhibition by cyclofenil than was chondroitin 4-sulphate proteoglycan synthesis. This was investigated further in the present study by using excess carrier protein (protein/drug ratio of 44: 1, w/w). Cultures were treated with various concentrations of cyclofenil (50-90 ,ug/ml) for 3 h and labelled with [35S] [8, 9] to chondroitin sulphates, which are polymerized on to proteoglycan core proteins in the Golgi apparatus [10, 11] . Thus, overall, these results indicate that the responses to cyclofenil of systems for the synthesis of different glycosaminoglycans differ subtly. In the Golgi this may depend on the response of specific enzymes, their particular location in the organelle or the availability of a particular core protein. In the case of hyaluronan, either the synthetase itself or its interaction with the plasma membrane may be affected. In all cases the availability of the UDP-sugar precursors could affect zthe ability to polymerize glycosaminoglycans, and this is considered below.
The effect of cyclofenil diphenol on different cell activities required for proteoglycan synthesis was examined. Chondrocyte (Fig. 2) whereas the amount of [3H]glucosamine incorporated into the UDP-N-acetylhexosamine pool was 28 % of that in control cultures. However, when the cultures were treated with 60 ,ug of cyclofenil/ml, the UDPsugar pools did not differ significantly from those in untreated cultures, even though the synthesis of chondroitin 4-sulphate and hyaluronan is much decreased under these conditions (Table 1) . Thus inhibition of UDP-sugar synthesis by cyclofenil does not appear to be the primary cause of the inhibitory effect of the drug on glycosaminoglycan synthesis, and even at high concentrations of the drug (90 /ug/ml) the decrease was greater than can be accounted for by the decrease in the total UDP-Nacetylhexosamine pool or incorporation of radiolabelled precursor into it. The results do not rule out the possibility that the cyclofenil diphenol might interfere with the uptake of cytosolic UDP-sugars into the Golgi apparatus for chondroitin sulphate synthesis.
Previous results showed that nitrophenyl fl-D-xyloside, an artificial substrate for initiating chondroitin sulphate synthesis, failed to promote synthesis when added to chondrocytes already treated for 2 h with cyclofenil [1] . Although this suggests that the drug inhibits xyloside-chondroitin sulphate synthesis, an alternative explanation is that it inhibits the uptake of the ,3-xyloside by the cell. To [14] . Cultures were treated as in Table 3 period are secreted from the cell at the normal rate after applying the drug [1] . This and other results suggest that whereas the secretory pathway from the Golgi apparatus to the plasma membrane remains intact during the early phase of treatment with cyclofenil, the biosynthetic function of the Golgi is rapidly disrupted. To test this, we labelled cultures for 20 h with [3H]serine so that all proteoglycan core protein in the cells would be 3H-labelled before chasing the cultures for 180 min with medium containing 90 ,ug of cyclofenil diphenol/ml. After solubilizing the cell layer with lithium dodecyl sulphate, this fraction and the chase medium were immunoprecipitated with a polyclonal antiserum (no. 1971) against core protein hyaluronanbinding region. The antiserum precipitates both core protein and complete proteoglycan, which were subsequently distinguished from one another by SDS/PAGE [15] . Recovery of the immunoprecipitated 3H-labelled molecules in the control chase cultures was about 95 % of that present in the cell layer at the 20 h labelling period (Table 4) . Negligible radioactivity was precipitated with non-immune rabbit serum (results not shown).
Only one high-molecular-mass component was detected in the immunoprecipitate from the control chase culture cell layer, and this did not migrate into the SDS/PAGE gel (Fig. 3a) [10, 17] , and is achieved by the co-ordinated action of a series of specific membrane-bound UDP-sugartransferases and sulphotransferases located in that organelle [18] . Swarm chondrocytes have an intracellular pool of about 0.5 ,tg of core protein/106 cells. Its half-life from translation to entry into the Golgi and the addition of glycosaminoglycan chains is -50 min, after which it is rapidly secreted from the cell with a half-life of 7 min [11, 15] [19] , it is of interest to identify their inhibitory mechanisms.
It seems unlikely that inhibition of UDP-sugar formation is a primary site for inhibition of proteoglycan synthesis by cyclofenil.
The drug brought about a significant inhibition of synthesis at concentrations (e.g. 60 ,ug/ml) which had no effect on UDPsugar pool sizes. This does not preclude an inhibition of transfer' of the precursors from the cytosol into Golgi compartments. With higher drug concentrations (90 ,g/ml) UDP-sugar pool sizes were decreased, as was the level of chondroitin sulphate synthesis in /-xyloside-stimulated cultures. However, there was a substantial residual level of synthesis in such cultures. This infers that adequate levels of precursors must be present and reach the site of chondroitin sulphate polymerization.
The ability of cyclofenil to decrease chondroitin sulphate synthesis in cultures which had been preloaded with nitrophenyl /?-D-xyloside indicates that one of its inhibitory actions is on the polymerization process itself. This may be by an effect of the drug on membrane structure. The results of the "25I-albumin experiments suggest that cyclofenil enters the cell in an unbound form. This could occur by transfer of the drug from the protein carrier to the cell membrane, or by uptake into the membrane of cyclofenil molecules from that small pool predicted to be soluble in the medium [1] . Transfer of the drug from the plasma membrane to the Golgi could occur either by endosome fusion with the latter [20] or via the cytosol. Intervesicle exchange of cholesterol via an aqueous phase has been demonstrated [21] . Incorporation of cyclofenil into the Golgi membranes may lead to a change in membrane fluidity. Ethinyl oestradiol decreases the phospholipid content and fluidity of ileal microvillus membranes [22] , and 17/J-oestradiol and tamoxifen lower membrane fluidity in MCF-7 and MDA-MB-436 human breast cancer cells [23] . Diethylstilboestrol, whose structure is closely related to that of cyclofenil [1] , caused rupture of the chormatophores of Rhodospirillum rubum through its interaction with the membrane and the hydrophobic domains of membrane proteins [24] . Similar interactions between cyclofenil and the Golgi membranes may interfere with the UDP-sugar transferases which are membranebound and, at least in the case of galactosyltransferase 1, dependent on intact membrane phospholipids [25] .
The electron microscopic changes noted in chondrocytes after exposure to cyclofenil include disassembly of the Golgi stack saccules, followed by dilation of the endoplasmic reticulum to form large ribosome-studded vesicles. Small vesicles present after the disappearance of Golgi saccules may be derived from the latter [2] . These changes resemble those occurring in cells treated with the fungal metabolite Brefeldin A [26, 27] and differ from those induced by monensin [10, 19] and diethylcarbamazine [28, 29] , which include swelling of the trans Golgi and the formation of large smooth vesicles. Brefeldin A blocks the protein secretory pathway by bringing about the disassembly of the cis; medial and trans Golgi. At least part of the Golgi membranes and their enzyme activities are redistributed to the endoplasmic reticulum [30] . The Golgi stack re-forms after withdrawal of Brefeldin A, as it does after removing cyclofenil [2] . These ultrastructural changes and their similarity to those induced by Brefeldin A raise the possibility that the core protein for the large chondroitin 4-sulphate proteoglycan remains in the endoplasmic reticulum in cyclofenil-treated cells, unable to gain access to any Golgi-derived structures still retaining glycosaminoglycan-polymerizing potential.
The differential inhibitory action of lower concentrations of cyclofenil on the large chondroitin 4-sulphate proteoglycan and the smaller chondroitin 6-sulphate-enriched proteoglycan is puzzling. By analogy with Brefeldin A [30] , if synthesis of the small proteoglycan occurred in a more cis-oriented compartment of the Golgi, one possibility might be that during cyclofenil treatment these membranes are relocated to the endoplasmic reticulum and retain some activity for synthesizing chondroitin 6-sulphate. However, there is currently no direct evidence for glycosaminoglycan synthesis outside the medial and trans Golgi compartments.
Finally, cyclofenil also affects some plasma membrane-as well as Golgi-related events. These include the synthesis of hyaluronan and the system A amino acid carrier. The effect on the former is more likely to be on the synthetase and its membrane association than on UDP-sugar availability, for the reasons discussed above. The effects of the drug at the plasma membrane are fairly specific, since transport of glucose and the activity of some amino acid carrier systems are little affected. It is noteworthy that other agents which perturb the protein secretory pathway, for example monensin, have widespread effects on cellular activities [19] .
